Meeting
2022 ASCO Annual Meeting
AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC.
Authors
Sanjay Popat
Lung Cancer Unit, Department of Medicine, The Royal Marsden Hospital, London, United Kingdom
Sanjay Popat , Enriqueta Felip , Edward S. Kim , Filippo de Marinis , Byoung Chul Cho , Martin Wermke , Adrianus De Langen , Roberto Ferrara , Stephan Kanzler , Fabiana Letizia Cecere , Domenico Galetta , Dae Ho Lee , Vanesa Gregorc , Ana Rodrigues , Christian Britschgi , Ahmadur Rahman , Diana Ndunda , Johannes Noe , Danny Lu , Benjamin Besse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04222972
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9159)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9159
Abstract #
TPS9159
Poster Bd #
134a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC).
First Author: Benjamin Besse
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2021 ASCO Annual Meeting
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.
First Author: Vivek Subbiah
Poster
2021 ASCO Annual Meeting
Addition of selpercatinib to overcome osimertinib resistance in non-small cell lung cancer (NSCLC) with acquired RET fusion detected in ctDNA at very low allele frequency.
First Author: Leeseul Kim